Translation of highly promising basic science research into clinical applications

American Journal of Medicine

Volumn 114, Issue 6, 2003, Pages 477-484

  Contopoulos Ioannidis, Despina G ^a,c   Ntzani, Evangelia E ^a   Ioannidis, John P A ^a,b,d  

^a UNIVERSITY OF IOANNINA   (Greece)

^b INSTITUTE OF COMPUTER SCIENCE   (Greece)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; EVALUATION; INFORMATION PROCESSING; OUTCOMES RESEARCH; PREDICTION; PRIORITY JOURNAL; PUBLICATION; RANDOMIZATION; STATISTICAL ANALYSIS;

EID: 0037447488     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00013-5     Document Type: Article

References (43)

1. Gannon F. Reaping the benefits of basic research. Nature. 1998;392:752.
2. British National Formulary. BNF 44. September 2002. British Medical Association and the Royal Pharmaceutical Society of Great Britain. Available at: http://www.bnf.org. Accessed October 2002.
3. Physician's Desk Reference. 56th ed. Montvale, New Jersey: Medical Economics Company Inc.; 2002. Available at: http://www.physician.pdr.net. Accessed October 2002.
4. Center for Devices and Radiological Health, U.S. Food and Drug Administration. Available at: http://www.fda.gov/cdrh/index.html. Accessed October 2002.
5. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
6. Inzelberg R, Carasso RL, Schechtman E, Nisipeanu P. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease. Clin Neuropharmacol. 2000;23:262-266.
7. Abboud RT, Ford GT, Chapman KR. Alpha 1-antitrypsin deficiency: a position statement of the Canadian Thoracic Society. Can Respir J. 2001;8:81-88.
8. Boeuf B, Gauvin F, Guerguerian AM, et al. Therapy of shock with naloxone: a meta-analysis. Crit Care Med. 1998;26:1910-1916.
9. Zanardi LR, Haber P, Mootrey GT, et al. Intussusception among recipients of rotavirus vaccine: reports to the vaccine adverse event reporting system. Pediatrics. 2001;107:e97.
10. Milord F, Pepin J, Loko L, et al. Efficacy and toxicity of eflornithine for treatment of Trypanosoma brucei gambiense sleeping sickness. Lancet. 1992;340:652-655.
11. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531-537.
12. Clark SJ, Beresford MW, Subhedar NV, Shaw NJ. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child. 2000;83:313-316.
13. Unverferth DV, Jagadeesh JM, Unverferth BJ, et al. Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. J Natl Cancer Inst. 1983;71:917-920.
14. Bracken MB, Shepard MJ, Collins WF, et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury. Results of the Second National Acute Spinal Cord Injury Study. N Engl J Med. 1990;322:1405-1411.
15. Brennand JE, Calder AA, Leitch CR, et al. Recombinant human relaxin as a cervical ripening agent. Br J Obstet Gynaecol. 1997;104:775-780.
16. Hellstrom E, Robert KH, Samuelsson J, et al. Treatment of myelodysplastic syndromes with retinoic acid and 1 alpha-hydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG). Eur J Haematol. 1990;45:255-261.
17. De Klerk NH, Musk AW, Ambrosini GL, et al. Vitamin A and cancer prevention. II: comparison of the effects of retinol and beta-carotene. Int J Cancer. 1998;75:362-367.
18. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88:1550-1559.
19. Floras P, Bidabe AM, Caille JM, et al. Double-blind study of effects of enkephalinase inhibitor on adverse reactions to myelography. AJNR Am J Neuroradiol. 1983;4:653-655.
20. Willer JC, Roby A, Ernst M. The enkephalinase inhibitor, GB 52, does not affect nociceptive flexion reflexes nor pain sensation in humans. Neuropharmacology. 1986;25:819-822.
21. Broomfield PH, Chopra R, Sheinbaum RC, et al. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med. 1988;319:1567-1572.
22. Attili AF, Capocaccia R, Carulli N, et al. Factors associated with gallstone disease in the MICOL experience. Multicenter Italian Study on Epidemiology of Cholelithiasis. Hepatology. 1997;26:809-818.
23. Sears SD, Clements ML, Betts RF, et al. Comparison of live, attenuated H1N1 and H3N2 cold adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis. 1988;158:1209-1219.
24. Steinhoff MC, Halsey NA, Fries LF, et al. The A/Mallard/6750/78 avian-human, but not the A/Ann Arbor/6/60 cold adapted, influenza A/Kawasaki/ 86 (H1N1) reassortant virus vaccine retains partial virulence for infants and children. J Infect Dis. 1991;163:1023-1028.
25. Ioannidis JPA, Haidich A-B, Lau J. Any casualties in the clash of randomised and observational evidence? BMJ. 2001;322:879-880.
26. Ioannidis JPA, Haidich AB, Pantazis N, et al. Comparison of evidence of treatment effects in randomized and nonrandomized studies. JAMA. 2001;286:821-830.
27. Jadad AR, Rennie D. The randomized controlled trial gets a middle-aged checkup. JAMA. 1998;279:319-320.
28. Comroe JH, Dripps RD. Scientific basis for the support of biomedical science. Science. 1976;192:105-111.
29. Mooney KG. Challenges faced by the pharmaceutical industry: training graduates for employment in pharmaceutical R&D. Eur J Pharm Sci. 2001;12:353-359.
30. Moy E, Mazzaschi AJ, Levin RJ, et al. Relationship between NIH research awards to US medical schools and managed care market penetration. JAMA. 1997;278:217-221.
31. Campbell EG, Weissman JS, Blumenthal D. Relationship between market competition and the activities and attitudes of medical school faculty. JAMA. 1997;278:222-226.
32. Campbell EG, Weissman JS, Moy E, Blumenthal D. Status of clinical research in academic health centers. Views from the research leadership. JAMA. 2001;286:800-806.
33. Whitcomb ME, Walter DL. Research training in six selected internal medicine fellowship programs. Ann Intern Med. 2000;133:800-807.
34. Schrier RW. Ensuring the survival of the clinician-scientist. Acad Med. 1997;72:589-594.
35. Rosenberg LE. The physician-scientist: an essential- and fragile-link in the medical research chain. J Clin Invest. 1999;103:1621-1626.
36. Williams GH, Wara DW, Carbone P. Funding for patient-oriented research. Critical strain on a fundamental linchpin. JAMA. 1997;278:227-231.
37. Rosenberg LE. Young physician-scientists: internal medicine's challenge. Ann Intern Med. 2000;13:831-832.
38. Nathan DG, Varmus HE. The National Institutes of Health and clinical research: a progress report. Nat Med. 2000;6:1201-1204.
39. Wyngaarden JB. The clinical investigator as an endangered species. N Engl J Med. 1979;301:1254-1259.
40. Isaakidis P, Pienaar E, Swingler GH, et al. Burden of disease and randomised evidence in sub-Saharan Africa: survey of research. BMJ. 2002;321:702-705.
41. Dauphinee D, Martin JB. Breaking down the walls: thoughts on the scholarship of integration. Acad Med. 2000;75:881-886.
42. Nathan DG. Clinical research: perceptions, reality and proposed solutions. National Institutes of Health Director's Panel on Clinical Research. JAMA. 1998;280:1427-1431.
43. Blumenthal D, Campbell EG, Weissman JS. The social missions of academic health centers. N Engl J Med. 1997;337:1550-1553.